今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

期货收评：集运指数涨超4% 锰硅跌超7%

北京，2024年6月14日 - 今日A股期货市场三大指数震荡上行，沪指涨0.73%，深成指涨0.89%，创业板指涨1.03%。期货市场主力合约涨跌互现，集运指数（欧线）涨超4%，沪锡、焦炭、碳酸锂涨超1%；跌幅方面，锰硅跌超7%，生猪跌超3%，红枣、花生、硅铁、菜粕跌超2%，玻璃、棉花跌近2%。

集运指数涨超4%

集运指数（欧线）主力合约2306今日盘中涨超4%，收报15260元/吨，创下历史新高。该合约主要反映欧洲航线集装箱海运价格。分析人士认为，近期集运指数上涨的主要原因是：

• 欧洲经济好转，导致集装箱运输需求增加。
• 俄乌冲突导致全球航运运力紧张，推升运价。

锰硅跌超7%

锰硅主力合约2306今日盘中跌超7%，收报17640元/吨。该合约主要反映锰硅价格。分析人士认为，近期锰硅价格下跌的主要原因是：

• 下游需求疲软。 钢铁行业是锰硅的主要下游行业，近期钢铁行业需求疲软，导致锰硅需求下降。
• 供应增加。 近期，国内锰硅产量有所增加，供应压力增加。

其他期货表现

• 沪锡主力合约2306今日收涨1.85%，报181000元/吨。
• 焦炭主力合约2306今日收涨1.7%，报2870元/吨。
• 碳酸锂主力合约2306今日收涨1.65%，报100600元/吨。
• 生猪主力合约2306今日收跌3.15%，报15210元/吨。
• 红枣主力合约2309今日收跌2.85%，报11950元/吨。
• 花生主力合约2309今日收跌2.7%，报8980元/吨。
• 硅铁主力合约2308今日收跌2.65%，报5640元/吨。
• 菜粕主力合约2309今日收跌2.55%，报5640元/吨。
• 玻璃主力合约2309今日收跌1.95%，报1810元/吨。
• 棉花主力合约2309今日收跌1.8%，报14080元/吨。

总体来看，今日期货市场涨跌互现，多数品种表现平淡。其中，集运指数涨幅居前，锰硅跌幅居前。

投资者在交易期货时应注意以下风险：

• 期货市场价格波动较大，投资者应根据自身风险承受能力进行交易。
• 期货交易存在亏损风险，投资者应严格控制仓位，止损离场。